Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel(®) therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension

The study was designed to evaluate the long-term efficacy and safety of the 28-day prolonged-release Autogel formulation of the somatostatin analogue lanreotide (Lan-Autogel) in unselected patients with acromegaly. The study comprised four phases: washout; a double-blind comparison with placebo, at...

Descripción completa

Detalles Bibliográficos
Autores principales: Melmed, Shlomo, Cook, David, Schopohl, Jochen, Goth, Miklos I., Lam, Karen S. L., Marek, Josef
Formato: Texto
Lenguaje:English
Publicado: Springer US 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807598/
https://www.ncbi.nlm.nih.gov/pubmed/19639415
http://dx.doi.org/10.1007/s11102-009-0191-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807598/
https://www.ncbi.nlm.nih.gov/pubmed/19639415
http://dx.doi.org/10.1007/s11102-009-0191-1

Ejemplares similares